Editorial Board
Jump to navigation
Jump to search
Our editorial board is comprised of cancer experts, organized primarily by disease focus. If you are interested in getting involved, please feel free to contact us with any questions or inquiries, at contact @ hemonc.org.
Editor-in-Chief
 |
Peter C. Yang, MD Boston, MA, USA |
Dr. Yang is board certified in Hematology and Medical Oncology; he practices at an academically affiliated institution in Massachusetts. |
Deputy Editor
 |
Andrew J. Cowan, MD Seattle, WA, USA |
Dr. Cowan is board certified in Hematology and Medical Oncology; he is the Research Director of the myeloma service at the Fred Hutch Cancer Center. He is an associate professor at the University of Washington. |
Associate Editors
| Cancer Registries | ||
|---|---|---|
 |
Mary Mesnard, BS, CTR |
Ms. Mesnard is a certified oncology data specialist with 36 years of experience working in hospital and more recently, central cancer registries. Her primary focus is managing central registries and quality assurance. |
| Evidence-based Oncology | ||
 |
Martin W. Schoen, MD, MPH Saint Louis University St. Louis, MO, USA |
Dr. Schoen is board certified in Hematology and Medical Oncology; he practices at the Saint Louis Veterans Affairs Medical Center. He is an assistant professor at Saint Louis University. |
| Pediatric Hematology/Oncology | ||
 |
Nicole M. Wood, DO University of Missouri Kansas City, MO, USA |
Dr. Wood is board certified in Pediatrics and Pediatric Hematology-Oncology; she practices at Children's Mercy Kansas City. She is an Assistant Professor of Pediatrics at the University of Missouri. |
| Radiation Oncology | ||
 |
Danielle S. Bitterman, MD Dana-Farber Cancer Institute Boston, MA, USA |
Dr. Bitterman is board certified in Radiation Oncology; she practices at Brigham and Women’s Hospital/Dana-Farber Cancer Institute. She is an Assistant Professor of Radiation Oncology at Harvard Medical School. |
| Supportive Oncology | ||
 |
Maryam B. Lustberg, MD, MPH Yale University New Haven, CT, USA |
Dr. Lustberg is board certified in Medicine and Medical Oncology; she is the director of the Breast Center at Smilow Cancer Hospital and chief of Breast Medical Oncology at Yale Cancer Center. She is an Associate Professor of Internal Medicine (Medical Oncology) at Yale University. She is the co-chair of Symptom Intervention Committee for Alliance Clinical Trials, and the 2022 president of the Multinational Association of Cancer Supportive Care (MASCC) |
Regional Associate Editors
| Asia | ||
|---|---|---|
| Unfilled | If you are interested in this role, please contact us at contact @ hemonc.org. | |
| Europe and United Kingdom | ||
 |
Mark P. Lythgoe, MBBS, PharmD Imperial College London London, England, UK |
Dr. Lythgoe is a medical oncologist, clinical pharmacist, and health services researcher. His work involves analyzing cancer drug approvals and regulatory pathways. |
| Middle East and North Africa | ||
| Unfilled | If you are interested in this role, please contact us at contact @ hemonc.org. | |
| Oceania | ||
 |
Georgina Kennedy, PhD Ingham Institute for Applied Medical Research Sydney, NSW, Australia |
Dr. Kennedy is a health data infrastructure specialist and data engineer. Her work involves harmonizing systemic anticancer therapy standards, including the eviQ resource of evidence-based, consensus driven cancer treatment protocols. |
 |
Salvatore (Sam) Fiorenza, MBBS, PhD, BSc(Hons), MPH, FRACP, FRCPA University of Sydney Camperdown, NSW, Australia |
Dr. Fiorenza is a haematologist and physician-scientist with an interest in treating malignant haematological conditions, especially acute myeloid leukemia and stem cell transplantation. Sam conducts research immunotherapy with a particular interest in CAR T-cell therapy. Sam is also the deputy director and medical lead of cellular therapy at Epworth HealthCare. |
| Latin America | ||
| Unfilled | If you are interested in this role, please contact us at contact @ hemonc.org. | |
| Sub-Saharan Africa | ||
 |
Clement Dove Okello, MMed, MBChB Uganda Cancer Institute Kampala, Uganda |
Clement Dove Okello is a consultant Clinical Haematologist at the Uganda Cancer Institute. He graduated with a Bachelor’s of Medicine and Bachelor’s of Surgery degree and a Master’s of Medicine degree in Internal Medicine from Makerere University, Uganda in 2007 and 2014 respectively. He also completed a Fellowship training in Clinical Haematology from McMaster University, Canada in 2016. Clement is passionate about improving patient care, clinical research and training of health care personnel in sub-Saharan Africa. Beyond his profession, he enjoys singing in a choir, gardening and nature walks. |
Section Editors
| Breast Oncology | ||
|---|---|---|
 |
Gayathri Nagaraj, MD Loma Linda, CA, USA |
Dr. Nagaraj is board certified in Hematology and Medical Oncology. She is an Associate Professor of Medicine at Loma Linda University and the Program Director of the Hematology and Medical Oncology fellowship program at Loma Linda University Health Education Consortium (LLUHEC). Her clinical practice focuses on breast cancer. |
| Dermatologic Oncology | ||
 |
Elizabeth Buchbinder, MD Boston, MA, USA |
Dr. Buchbinder is board certified in Medical Oncology; she is a senior physician at the Dana-Farber Cancer Institute. She is an Assistant Professor of Medicine at Harvard Medical School. |
| Endocrine Oncology | ||
| Unfilled | If you are interested in this role, please contact us at contact @ hemonc.org. | |
| Gastrointestinal Oncology, Intestinal | ||
 |
Travis Zack MD, PhD San Francisco, CA, USA |
Dr. Zack is board certified in Internal Medicine and board eligible for Medical Oncology. He is an Assistant Professor of Medicine at the University of California, San Francisco. |
| Gastrointestinal Oncology, Extraintestinal | ||
 |
Eric I. Marks, MD Boston, MA, USA |
Dr. Marks is board certified in Medical Oncology; he practices at Boston Medical Center and is an Assistant Professor of Medicine at Boston University School of Medicine. |
| Genitourinary Oncology | ||
 |
Ali Raza Khaki, MD Palo Alto, CA, USA |
Dr. Khaki is a Clinical Assistant Professor of Medicine/Oncology at Stanford University School of Medicine and genitourinary medical oncology at Stanford Cancer Center. He is board certified in Hematology and Medical Oncology. |
| Gynecologic Oncology | ||
 |
Alaina J. Brown, MD, MPH Nashville, TN, USA |
Dr. Brown is board certified in Gynecologic Oncology and Obstetrics and Gynecology; she practices at the Vanderbilt-Ingram Cancer Center. She is an Associate Professor of Obstetrics and Gynecology at Vanderbilt University. |
| e'Head & Neck Cancer' | ||
 |
Aditya Shreenivas, MD, MS Duarte, CA, USA |
Dr. Shreenivas is an Assistant Professor in the Department of Gastrointestinal and Head & Neck Medical Oncology at the City of Hope Comprehensive Cancer Center – Duarte Campus. Dr. Shreenivas is board certified in Internal Medicine, Hematology, and Medical Oncology. |
| Mesothelioma | ||
 |
Marjorie G. Zauderer, MD, MS, FACP New York, NY, USA |
Marjorie G. Zauderer, MD, MS, FACP is Section Chief, Hematology and Medical Oncology at the Westchester Medical Center. She received her medical degree from Columbia University's College of Physicians and Surgeons, completed her residency in Internal Medicine at the New York-Presbyterian Hospital Columbia University Medical Center, and completed fellowship and chief fellowship in medical oncology at Memorial Sloan Kettering Cancer Center. Dr. Zauderer cares for patients with mesothelioma and other thoracic malignancies. Her practice aims to provide personalized care to patients throughout the course of their treatment based not only on the type of cancer and its genetics but the individual priorities of each and every patient and family. She is also an active translational and clinical researcher and focuses on the development of new therapies for the treatment of mesothelioma and lung cancers. She has received several federally funded grants for her research including a Department of Defense (DOD) Career Development Award, DOD Translational Team Science Award, and 2 R01s. She reviews grants for foundations as well as the Department of Defense and National Cancer Institute. Dr. Zauderer has lectured and presented her work throughout the United States and international thoracic community and has authored/co-authored more than 80 peer-reviewed oncology manuscripts. Dr. Zauderer is board certified in Medical Oncology. |
| Neuro-Oncology | ||
 |
Seema Nagpal, MD Palo Alto, CA, USA |
Dr. Nagpal is board certified in Neurology and UCNS certified in Neuro-Oncology; she practices at Stanford Health Care. She is a Clinical Professor of Neurology at Stanford University |
| Sarcoma | ||
 |
Elizabeth J. Davis, MD Nashville, TN, USA |
Dr. Davis is board certified in Medical Oncology; she practices at the Vanderbilt-Ingram Cancer Center and is the medical director of the Clinical Trials Office. She is an associate professor at Vanderbilt University. |
| Thoracic Oncology | ||
 |
Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN, USA |
Dr. Kulkarni is board certified in Medical Oncology; he practices and is an Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation at the University of Minnesota. |
| Acute Leukemias | ||
 |
Ashwin Kishtagari, MD Vanderbilt University Nashville, TN, USA |
Dr. Kishtagari practices at Vanderbilt University Medical Center. He is an Assistant Professor of Medicine (Hematology/Oncology) at Vanderbilt University. He is board-certified in Internal Medicine and Medical Oncology. |
| Myeloproliferative Neoplasms and Myelodysplastic Syndromes | ||
 |
Sanjay R. Mohan, MD, MSCI Nashville, TN, USA |
Dr. Mohan is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University. |
| Aggressive Lymphomas & Lymphoproliferative disorders | ||
 |
Tarsheen K. Sethi, MD, MSCI Yale University New Haven, CT, USA |
Dr. Sethi is board certified in Hematology and Medical Oncology; she practices at the Smilow Cancer Hospital at Yale New Haven. She is an assistant professor at Yale University. |
| Indolent Lymphomas | ||
 |
Sanjai Sharma, MD Visalia, CA, USA |
Dr. Sharma is board certified in Hematology and Medical Oncology; he practices at the Sequoia Regional Cancer Center. |
| Plasma Cell Dyscrasias | ||
 |
Samuel M. Rubinstein, MD University of North Carolina Chapel Hill, NC, USA |
Dr. Rubinstein is board certified in Hematology and Medical Oncology; he is a clinical assistant professor and malignant hematologist at the University of North Carolina Chapel Hill and an associate member of the Lineberger Comprehensive Cancer Center. His primary clinical and research area of interest is plasma cell dyscrasias, and he is focused on clinical trials designed to improve the standard of care of patients with these disorders. In addition to clinical trials, Dr. Rubinstein has an informatics background, which he has leveraged to develop multiple prognostic scoring tools that are useful in the management of patients with plasma cell dyscrasias. |
| T-cell and NK-cell neoplasms | ||
 |
Bhagirathbhai Dholaria, MBBS Nashville, TN, USA |
Dr. Dholaria is currently an associate professor in the Department of Hematology-Oncology at Vanderbilt University Medical Center, Nashville, TN. His areas of specialization and primary research focus are lymphoid neoplasms, plasma cell malignancies, adoptive cellular therapies, and stem cell transplantation. He has conducted studies investigating the outcomes of patients with non- Hodgkin lymphoma and acute leukemia undergoing chimeric antigen receptor T-cell (CAR-T) therapies. He is involved in translational research investigating the biomarkers of CAR T-cell therapy-associated toxicities. He has also conducted several observational studies utilizing cancer registries to study transplant outcomes of acute leukemia patients and presented his findings in national meetings. His team's work on stem cell transplantation has been published in multiple manuscripts. His current research efforts are focused on testing novel agents to address relapse after CAR T therapy in lymphoma and multiple myeloma. Dr. Dholaria is board certified in Hematology and Medical Oncology. |
| Histiocytic Disorders | ||
 |
Gaurav Goyal, MBBS UAB Birmingham, AL, USA |
Dr. Goyal is board certified in Hematology and Medical Oncology; he practices at the O'Neal Comprehensive Cancer Center at UAB Medicine. He is an assistant professor at UAB (The University of Alabama at Birmingham). |
| Pediatric Blastomas & Extracranial Germ Cell Tumors | ||
 |
Elaine M. Fan, MD, MS Wichita, KS, USA |
Dr. Fan is a Clinical Assistant Professor of Pediatrics at the University of Kansas and practices at Wesley Medical Center. She is particularly interested in applying clinical informatics to improve clinical workflow efficiency, enhance provider and patient experience and, ultimately, improve health outcomes in pediatrics and pediatric hematology-oncology. Dr. Fan is board-certified in Pediatrics and Clinical Informatics, and board-eligible in Pediatric Hematology-Oncology. |
| Pediatric Leukemia & Lymphoma | ||
 |
David Noyd, MD, MPH University of Washington Seattle, WA, USA |
Dr. Noyd is board certified in Pediatrics and board eligible in Pediatric Hematology-Oncology; he practices at Seattle Children's Hospital. He is an Assistant Professor of Pediatrics at the University of Washington. |
| Pediatric Neuro-Oncology & Solid Tumors | ||
| Unfilled | If you are interested in this role, please contact us at contact @ hemonc.org. | |
| Transplant | ||
 |
Talal Hilal, MD Mayo Clinic Phoenix, AZ, USA |
Dr. Hilal is a hematologist/oncologist and bone marrow transplant physician with a clinical focus on chronic lymphocytic leukemia, lymphoid malignancies, and rare histiocytic neoplasms. Dr. Hilal attended medical school at the Royal College of Surgeons in Ireland. He obtained training in internal medicine at the University of Kentucky and in hematology/oncology at the Mayo Clinic in Phoenix, Arizona where he served as Chief Fellow. Dr. Hilal is board certified in Hematology and Medical Oncology; he practices at Mayo Clinic Arizona. He is an assistant professor at the Mayo Clinic. |
| Classical Hematology | ||
 |
Benjamin Tillman, MD Vanderbilt University Nashville, TN, USA |
Dr. Tillman is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an Assistant Professor of Medicine (Hematology/Oncology) |
| Guidelines | ||
 |
Sandeep K. Jain, MD Brown University Providence, RI, USA |
Dr. Jain is a senior hematology/oncology fellow at Brown University; he is board certified in Internal Medicine. |
| Living Systematic Reviews | ||
 |
Irbaz Bin Riaz, MD, PhD, MS Mayo Clinic Phoenix, AZ, USA |
Dr. Riaz is board certified in Internal Medicine and Medical Oncology; he is an Assistant Professor of Medicine at Mayo Clinic, Arizona. |
Pharmacy Editors
| Clinical Pharmacology | ||
|---|---|---|
 |
Grace Baek, PharmD, BCOP UW Medicine / Fred Hutchinson Cancer Center Seattle, WA, USA |
Dr. Baek is a Clinical Oncology Pharmacist at the Fred Hutchinson Cancer Center. She is Board Certified in Oncology Pharmacy. |
 |
Nicholas Bitz, PharmD, MBA, MSPGx University Hospitals Cleveland Medical Center Cleveland, OH, USA |
Dr. Bitz graduated with a PharmD from South Dakota State University in 2015, and entered community pharmacy practice for two years before starting as a clinical pharmacist with University Hospitals in Cleveland, OH in 2017. He began working in outpatient oncology infusion in 2018 and worked in that space for 5 years, before beginning a role as a oncology clinical specialist at University Hospitals Seidman Cancer Center in 2023, specializing in multiple myeloma and lymphoma. He earned an MBA from Dakota State University in 2022 and earned as Masters in Pharmacogenomics from Manchester University in 2024. |
 |
Sotirios Diamantoudis, MPharmc Aristotle University Thessaloniki, Greece |
Mr. Diamantoudis is currently a Pharmacy student at the Aristotle University of Thessaloniki, Greece. Interested in the fields of biopharmaceuticals, oncology, immunotherapies and cell and gene therapies. |
 |
Rachel Feaster, PharmD, BCOP, BCPS Fred Hutchinson Cancer Center Seattle, WA, USA |
Rachel Feaster is a board certified clinical oncology pharmacist with a specialized focus in community oncology care and integrative medicine. Rachel received her Doctor of Pharmacy degree from the University of Missouri-Kansas City and completed her PGY1 residency at the Veterans Affairs Puget Sound Health Care System in Seattle, WA. Rachel is also board certified in pharmacotherapy and has a diverse background including 10+ years of professional experience in ambulatory, inpatient, pharmacogenomics, and oncology care. She currently practices as a clinical oncology pharmacist at Fred Hutchinson Cancer Center in Seattle, WA. |
 |
Austin Fitts, PharmD National Cancer Institute Silver Springs, MD, USA |
Dr. Fitts is a Postdoctoral Fellow at the National Cancer Institute. |
 |
Laura Roccograndi, PharmD, BCOP Fred Hutchinson Cancer Center Seattle, WA, USA |
Dr. Roccograndi is a clinical pharmacy specialist at the Fred Hutchinson Cancer Center. She is Board Certified in Oncology Pharmacy. |
 |
Emily Waite, PharmD, BCOP Children's of Alabama Birmingham, AL, USA |
Emily S. Waite, Pharm.D., BCOP, is a Pediatric Hematology/Oncology Pharmacist with the Alabama Center for Childhood Cancer and Blood Disorders at Children's of Alabama in Birmingham. Emily grew up in Ooltewah, Tennessee, moving to Birmingham to complete here undergraduate degree at the UAB. After earning her Bachelor of Science degree in biology from UAB, Dr. Waite earned her Doctor of Pharmacy degree from Auburn University Harrison School of Pharmacy. She completed a PGY1 Pharmacy Practice Residency at Children's of Alabama. For the past 14 years, Emily has provided inpatient and outpatient care for the Hematology/Oncology Division at Children's of Alabama. Emily now works as a Beacon and Willow Analyst for the informatics department, while continuing to serve as a clinical resource for the Center for Childhood Cancer and Blood Disorders at Children's of Alabama in Birmingham. She is Board Certified in Oncology Pharmacy. |
 |
Bradley Yelvington, PharmD, BCOP Vanderbilt University Medical Center Nashville, TN, USA |
Dr. Yelvington is a Board-Certified Oncology Pharmacist practicing since 2017 at Vanderbilt University Medical Center in Adult Malignant Hematology. He is Board Certified in Oncology Pharmacy. |
 |
Carolnn Yong, PharmD, BCPS, BCOP Providence Holy Cross Medical Center Mission Hills, CA, USA |
Dr. Yong is a Board Certified Oncology Pharmacist. |
Page Editors
- Jon Arnason, MD (Beth Israel Deaconess Medical Center, Boston, MA, USA)
- Brianna Bakow, MD (Brigham and Women's Hospital, Boston, MA, USA)
- Joshua Brandstadter, MD, PhD, MSc (University of Pennsylvania, Philadelphia, PA, USA)
- Teja Ganta, MD (Icahn School of Medicine at Mount Sinai, Manhattan, NY, USA)
- Michael J. Glover, MD (Stanford University, Palo Alto, CA, USA)
- Laura S. Graham, MD (University of Colorado, Anschutz Medical Campus, Aurora, CO, USA)
- Matthew Hadfield, DO (Brown University, Providence, RI, USA)
- Shalin Kothari, MD (Yale University, New Haven, CT, USA)
- Mary L. Kwok, MD, FACP (Fred Hutchinson Cancer Center, Seattle, WA, USA)
- Emily A. Mann, MD (Boston University, Boston, MA, USA)
- Eric I. Marks, MD (Boston University, Boston, MA, USA)
- Francesca Montanari, MD (Yale University, New Haven, CT, USA)
- Ryan H. Nguyen, DO (University of Illinois at Chicago, IL, USA)
- Michael K. Rooney, MD (MD Anderson Cancer Center, Houston, TX, USA)
- Eric K. Singhi, MD (MD Anderson Cancer Center, Houston, TX, USA)
- Leyre Zubiri, MD, PhD (Massachusetts General Hospital, Boston, MA, USA)
COI Disclosures
Please see our conflict of interest page for more details. Disclosures here are for COI within 24 months of the date of disclosure unless otherwise noted.
| Name | Research funding (to institution) | Other (honoraria, travel support, significant ownership interests, etc.) | Date of disclosure |
|---|---|---|---|
| Jon Arnason | Nothing to disclose | Speaker: Bristol-Myers Squibb & Regeneron Travel support: Regeneron |
2024-08-19 |
| Grace Baek | Nothing to disclose | Education: Postgraduate Healthcare, LLC (funding from Bristol-Myers Squibb) | 2024-10-17 |
| Brianna Bakow | Nothing to disclose | Nothing to disclose | 2023-08-27 |
| Danielle S. Bitterman | Research funding from ACS, ASTRO, and the NIH | Scientific Advisory Board: MercurialAI | 2024-08-21 |
| Joshua Brandstadter | Nothing to disclose | Consulting: Recordati Rare Disease | 2024-07-17 |
| Alaina J. Brown | NIH | Nothing to disclose | 2024-08-02 |
| Elizabeth Buchbinder | NIH; Clinical trial support from Lilly, Novartis, Partners therapeutics, Genentech and BVD. | Consultant/advisory board member for Pfizer, Werewolf pharma, Merck, Iovance, Sanofi, Xilio, Anaveon, Obsidian and Novartis. | 2024-12-02 |
| Andrew Cowan | Janssen, BMS, Juno/Celgene, Sanofi, Regeneron, IGM BIosciences, Nektar, Harpoon, Adaptive Biotechnologies, Caelum, Abbvie | Consultancy: Sebia, Janssen, BMS, Sanofi, HopeAI, Adaptive Biotechnologies, Abbvie | 2024-09-01 |
| Elizabeth J. Davis | Trial funding: Incyte, Cornerstone, Cogent, Bio Atla, Actuate | Consulting: Deciphera, Aadi, SpringWorks | 2024-11-05 |
| Bhagirathbhai Dholaria | Research funding: Janssen, Angiocrine, Pfizer, Poseida, MEI, Orcabio, Wugen, Allovir | Consulting/Advisory Board: Jazz, Gamida Cell, MJH BioScience, Arivan Research, BEAM therapeutics, Janssen, Atheneum; Study steering committee: Gamida Cell | 2024-08-01 |
| Elaine Fan | Nothing to disclose | Consulting: Westat | 2024-07-31 |
| Rachel Feaster | Nothing to disclose | Freelance medical writer for GoodRx and Pharmacy Times. Served as faculty member for Pharmacy Times symposia. | 2024-03-13 |
| Austin Fitts | Nothing to disclose | Consulting: Westat | 2024-08-07 |
| Teja Ganta | Nothing to disclose | Nothing to disclose | 2024-11-08 |
| Michael J. Glover | Nothing to disclose | Nothing to disclose | 2024-11-04 |
| Gaurav Goyal | NIH/NCI | Consultancy: Recordati; Advisory Board: Opna Bio, Seagen, Sobi | 2024-11-22 |
| Laura Graham | Nothing to disclose | Nothing to disclose | 2023-09-11 |
| Matthew Hadfield | Nothing to disclose | Nothing to disclose | 2024-08-01 |
| Talal Hilal | NIH/NCI | Consulting/Advisory Board: Incyte; Editorship: Springer | 2024-08-07 |
| Sandeep K. Jain | Nothing to disclose | HemOnc.org internship (2023-2024) | 2024-06-13 |
| Georgina Kennedy | Nothing to disclose | Nothing to disclose | 2024-11-01 |
| Ali R. Khaki | 23andMe, Janssen, Acrivon Therapeutics | Consulting/Advisory Board: Seagen/Astellas Travel: BCAN; SABCS Honoraria: Onclive CME |
2024-08-13 |
| Ashwin Kishtagari | Nothing to disclose | Consulting/Advisory Board: Sobi (CTI biopharma), Geron, Morphosys, Rigel, Servier Pharmaceuticals, Syndax | 2025-01-02 |
| Shalin Kothari | Nothing to disclose | Consulting/Advisory Board: ADC therapeutics | 2024-09-30 |
| Amit Kulkarni | Research Funding to Institution: Astra Zeneca | Speaker Bureau: Regeneron; Consulting/Advisory Board: Exelixis; Stock and Other Ownership Interests: Merck, Exact Sciences, Eli Lilly, Abbvie. | 2023-08-03 |
| Mary L. Kwok | BeiGene | Bristol Myers Squibb Foundation | 2024-11-01 |
| Wayne H. Liang | Nothing to disclose | Consulting/Advisory Board: Westat, ChemoMap, Genoplex.ai | 2024-10-17 |
| Maryam Lustberg | AstraZeneca, Novartis | Consulting/Advisory Board: Novartis, Lily, Gilead, Menarini | 2024-11-02 |
| Mark P. Lythgoe | Nothing to disclose | Nothing to disclose | 2024-11-03 |
| Emily A. Mann | Nothing to disclose | Nothing to disclose | 2025-01-02 |
| Eric Marks | Research funding: Merck | Consulting/Advisory Board: Sermo, Medscape, Brand Institute, M3 | 2023-06-28 |
| Mary Mesnard | Nothing to disclose | Nothing to disclose | 2024-07-31 |
| Sanjay R. Mohan | Research funding: NCCN, Ichnos, Incyte, Kartos, Karyopharm, Taiho | Nothing to disclose | 2024-12-31 |
| Francesca Montanari | Nothing to disclose | Honoraria: Acrotech, BeiGene | 2024-11-02 |
| Gayathri Nagaraj | Nothing to disclose | Consulting: SyndevRx, Lilly, AstraZeneca | 2024-07-16 |
| Seema Nagpal | Trial funding: Agios, PharmAbcine, Insightec, Berg, Inovio | Nothing to disclose | 2024-08-05 |
| Ryan Nguyen | Exelixis (research funding to institution) | Genomeweb (honoraria), Merck (speaker's bureau) | 2023-09-16 |
| David Noyd | Nothing to disclose | Consulting/Advisory Board: Westat | 2024-07-31 |
| Irbaz Bin Riaz | NIH/NCI | Nothing to disclose | 2024-11-01 |
| Laura Roccograndi | Nothing to disclose | Pharmacy Times CE | 2024-03-03 |
| Michael K. Rooney | Nothing to disclose | Nothing to disclose | 2024-08-14 |
| Samuel R. Rubinstein | Nothing to disclose | Consulting/Advisory Board: Janssen, Sanofi, LAVA therapeutics, EUSA pharma, Roche Diagnostics, and Bristol-Myers Squibb | 2024-10-17 |
| Martin Schoen | St. Louis Veterans Affairs Medical Center, Congressionally Directed Medical Research Program | Consulting/Advisory Board: Doximity, Pfizer | 2023-08-11 |
| Tarsheen Sethi | Nothing to disclose | Nothing to disclose | 2024-11-01 |
| Sanjai Sharma | Nothing to disclose | Nothing to disclose | 2023-09-11 |
| Aditya Shreenivas | Research funding to Medical College of Wisconsin from Natera. Research support for data analysis and publication, Caris to Medical College of Wisconsin | Advisory board Taiho Oncology in Medical College of Wisconsin; Investigator Target Cancer Foundation (not for profit) | 2024-12-16 |
| Eric K. Singhi | Nothing to disclose | Consulting/Advisory Board: AstraZeneca, Novocure, Amgen, Janssen, Regeneron, Bayer, BMS, BI, Eli Lilly | 2024-12-31 |
| Benjamin F. Tillman | Nothing to disclose | Nothing to disclose | 2024-11-02 |
| Emily Waite | Nothing to disclose | Speaker's Bureau: Servier | 2024-03-06 |
| Nicole M. Wood | Nothing to disclose | Consulting/Advisory Board: Westat | 2024-07-31 |
| Peter C. Yang | Nothing to disclose | Ownership: HemOnc.org Stock: Merck, Pfizer |
2024-10-17 |
| Carolnn Yong | Nothing to disclose | Nothing to disclose | 2024-03-04 |
| Travis Zack | Nothing to disclose | Nothing to disclose | 2023-09-05 |
| Marjorie Zauderer | Memorial Sloan Kettering receives research funding from the Department of Defense, the National Institutes of Health, Precog, GlaxoSmithKline, Epizyme, Polaris, Sellas Life Sciences, Bristol Myers Squibb, Millenium/Takeda, Curis, and Atara for research conducted by Dr. Zauderer. | In the last 3 years, Dr. Zauderer has received consulting fees from Curis, Ikena, Takeda, GlaxoSmithKline, Aldeyra Therapeutics, Novocure, and Atara and honoraria for CME content from PER, Medscape, Research to Practice, Medical Learning Institute and OncLive. Dr. Zauderer serves as Chair of the Board of Directors of the Mesothelioma Applied Research Foundation, uncompensated. | 2024-08-08 |
| Leyre Zubiri | Nothing to disclose | Nothing to disclose | 2024-12-16 |